Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
Highlights,Zacks Research adjusted its Q2 2025 EPS estimate for Sanofi to $0.93, slightly decreasing from a prior prediction ...
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the ...
B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ...
Technology Networks spoke to Professor Thomas Rademacher, co-founder, executive director and CEO at Gylden Pharma Limited, to ...
As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...
Intellia Therapeutics Inc. is shaking up its Cambridge and Waltham real estate footprints. The gene-editing company h as ...
Equities research analysts at National Bank Financial reduced their Q2 2025 EPS estimates for Canadian Tire in a research ...
Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment ...
US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results